Overview

A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

Status:
Completed

Trial end date:
2013-08-01

Target enrollment:

Participant gender:

Summary

This is a Phase 1 Open-Label, Parallel-Group, Single-Dose Study to evaluate the Pharmacokinetics of GS-5816 in subjects with normal hepatic function and moderate or severe hepatic impairment.

Phase:

Phase 1

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Velpatasvir